Endocrinology, Diabetes & Metabolism Case Reports (Dec 2018)

Identification of a novel large CASR deletion in a patient with familial hypocalciuric hypercalcemia

  • Alejandro García-Castaño,
  • Leire Madariaga,
  • Sharona Azriel,
  • Gustavo Pérez de Nanclares,
  • Idoia Martínez de LaPiscina,
  • Rosa Martínez,
  • Inés Urrutia,
  • Aníbal Aguayo,
  • Sonia Gaztambide,
  • Luis Castaño

DOI
https://doi.org/10.1530/EDM-18-0114
Journal volume & issue
Vol. 1, no. 1
pp. 1 – 5

Abstract

Read online

Familial hypocalciuric hypercalcemia type I is an autosomal dominant disorder caused by heterozygous loss-of-function mutations in the CASR gene and is characterized by moderately elevated serum calcium concentrations, low urinary calcium excretion and inappropriately normal or mildly elevated parathyroid hormone (PTH) concentrations. We performed a clinical and genetic characterization of one patient suspected of familial hypocalciuric hypercalcemia type I. Patient presented persistent hypercalcemia with normal PTH and 25-hydroxyvitamin D levels. The CASR was screened for mutations by PCR followed by direct Sanger sequencing and, in order to detect large deletions or duplications, multiplex ligation-dependent probe amplification (MLPA) was used. One large deletion of 973 nucleotides in heterozygous state (c.1733-255_2450del) was detected. This is the first large deletion detected by the MLPA technique in the CASR gene.